Applied Therapeutics Financial Statements (APLT)
|
|
|
|
Report date
|
|
|
13.03.2020 |
18.03.2021 |
10.03.2022 |
23.03.2023 |
06.03.2024 |
|
07.11.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
0.000 |
0.000 |
0.000 |
0.000 |
9.99 |
|
1.12 |
|
Operating Income, bln rub |
|
|
-45.6 |
-94.5 |
-105.6 |
-83.0 |
-64.5 |
|
-92.3 |
|
EBITDA, bln rub |
? |
|
-45.6 |
-94.5 |
-105.2 |
-82.1 |
-64.5 |
|
-92.2 |
|
Net profit, bln rub |
? |
|
-45.4 |
-93.0 |
-104.6 |
-81.7 |
-119.8 |
|
-187.3 |
|
|
OCF, bln rub |
? |
|
-36.3 |
-78.2 |
-90.7 |
-78.1 |
-55.2 |
|
-81.8 |
|
CAPEX, bln rub |
? |
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
FCF, bln rub |
? |
|
-36.3 |
-78.2 |
-90.7 |
-78.1 |
-55.2 |
|
-81.8 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
45.6 |
94.5 |
105.6 |
83.0 |
74.2 |
|
65.2 |
|
Cost of production, bln rub |
|
|
0.023 |
0.380 |
0.415 |
0.441 |
53.9 |
|
0.588 |
|
R&D, bln rub |
|
|
32.4 |
61.8 |
62.6 |
55.6 |
53.9 |
|
40.3 |
|
Interest expenses, bln rub |
|
|
0.093 |
0.559 |
0.555 |
|
0.000 |
|
0.721 |
|
|
Assets, bln rub |
|
|
48.4 |
104.5 |
89.9 |
38.4 |
54.8 |
|
106.6 |
|
Net Assets, bln rub |
? |
|
32.6 |
81.9 |
62.5 |
4.06 |
-17.1 |
|
5.89 |
|
Debt, bln rub |
|
|
2.04 |
1.74 |
1.33 |
0.891 |
0.777 |
|
1.97 |
|
Cash, bln rub |
|
|
38.9 |
96.8 |
80.8 |
30.6 |
49.9 |
|
98.9 |
|
Net debt, bln rub |
|
|
-36.8 |
-95.1 |
-79.5 |
-29.7 |
-49.1 |
|
-96.9 |
|
|
Ordinary share price, rub |
|
|
27.3 |
22.0 |
8.95 |
0.760 |
3.35 |
|
2.30 |
|
Number of ordinary shares, mln |
|
|
12.8 |
22.0 |
25.6 |
37.8 |
84.2 |
|
14.4 |
|
|
Market cap, bln rub |
|
|
350 |
483 |
229 |
29 |
282 |
|
33 |
|
EV, bln rub |
? |
|
313 |
388 |
150 |
-1 |
233 |
|
-64 |
|
Book value, bln rub |
|
|
33 |
82 |
63 |
4 |
-17 |
|
6 |
|
|
EPS, rub |
? |
|
-3.54 |
-4.23 |
-4.09 |
-2.16 |
-1.42 |
|
-13.0 |
|
FCF/share, rub |
|
|
-2.83 |
-3.56 |
-3.54 |
-2.06 |
-0.65 |
|
-5.67 |
|
BV/share, rub |
|
|
2.54 |
3.73 |
2.44 |
0.11 |
-0.20 |
|
0.41 |
|
|
EBITDA margin, % |
? |
|
|
|
|
|
-645.8% |
|
-8 208% |
|
Net margin, % |
? |
|
|
|
|
|
-1 198% |
|
-16 679% |
|
FCF yield, % |
? |
|
-10.4% |
-16.2% |
-39.6% |
-271.7% |
-19.5% |
|
-246.5% |
|
ROE, % |
? |
|
-139.2% |
-113.5% |
-167.3% |
-2 012% |
698.5% |
|
-3 179% |
|
ROA, % |
? |
|
-93.8% |
-89.0% |
-116.4% |
-212.9% |
-218.4% |
|
-175.8% |
|
|
P/E |
? |
|
-7.71 |
-5.20 |
-2.19 |
-0.35 |
-2.36 |
|
-0.18 |
|
P/FCF |
|
|
-9.64 |
-6.18 |
-2.53 |
-0.37 |
-5.12 |
|
-0.41 |
|
P/S |
? |
|
|
|
|
|
28.2 |
|
29.6 |
|
P/BV |
? |
|
10.7 |
5.90 |
3.66 |
7.08 |
-16.5 |
|
5.63 |
|
EV/EBITDA |
? |
|
-6.87 |
-4.11 |
-1.42 |
0.01 |
-3.61 |
|
0.69 |
|
Debt/EBITDA |
|
|
0.81 |
1.01 |
0.76 |
0.36 |
0.76 |
|
1.05 |
|
|
CAPEX/Revenue, % |
|
|
|
|
|
|
0.00% |
|
0 |
|
| Applied Therapeutics shareholders |
